Karyopharm Schedule 13G: Acorn, Hove Report 6.7% Stake

Karyopharm Therapeutics Inc. Schedule 13G disclosure: Acorn-affiliated investment vehicles and Anders Hove report combined beneficial ownership positions in the issuer's common stock.

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. Schedule 13G disclosure: Acorn-affiliated investment vehicles and Anders Hove report combined beneficial ownership positions in the issuer's common stock.

Acorn Bioventures, L.P. reports 637,608 shares (2.8%); Acorn Bioventures 2, L.P. reports 880,505 shares (3.9%); Anders Hove reports 1,518,113 shares (6.7%). The percentages are calculated using 22,662,943 shares outstanding as of May 7, 2026. Signatures are dated 05/15/2026.

Insights

Corporate Governance Analyst

Acorn entities and Anders Hove disclosed minority stakes totaling visible positions in Karyopharm.

The filing lists specific beneficial ownership counts and voting/dispositive power allocations across related entities: shared voting and dispositive power figures are reported for each Acorn vehicle and for Mr. Hove as manager. The disclosure ties percentages to May 7, 2026 outstanding shares.

Implications depend on future activity by these holders; subsequent filings would show any changes. Cash‑flow treatment is not stated in the excerpt.

Key Figures

Shares outstanding: 22,662,943 shares Acorn Bioventures ownership: 637,608 shares Acorn Bioventures 2 ownership: 880,505 shares +2 more

5 metrics

Shares outstanding 22,662,943 shares as of May 7, 2026

Acorn Bioventures ownership 637,608 shares 2.8% of outstanding shares

Acorn Bioventures 2 ownership 880,505 shares 3.9% of outstanding shares

Anders Hove ownership 1,518,113 shares 6.7% of outstanding shares

Signature date 05/15/2026 filing signatures dated

Key Terms

beneficially owned, shared voting power, Form 10-Q, Schedule 13G

4 terms

beneficially owned regulatory

"Amount beneficially owned: The information required by Items 4(a) - (c) is set forth"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared voting power governance

"Shared Voting Power 1,518,113.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

Form 10-Q regulatory

"as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

Schedule 13G regulatory

"Item 1. (a) Name of issuer: Karyopharm Therapeutics Inc."

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Acorn Bioventures report in KPTI?

Acorn Bioventures, L.P. reports 637,608 shares (2.8%), calculated using 22,662,943 shares outstanding as of May 7, 2026. This figure appears in the report's cover‑page ownership rows and Item 4.

How many shares does Acorn Bioventures 2, L.P. own in KPTI?

Acorn Bioventures 2, L.P. reports 880,505 shares (3.9%) of common stock, based on the issuer's reported 22,662,943 shares outstanding as of May 7, 2026, per Item 4 of the filing.

What is Anders Hove’s reported ownership in KPTI?

Anders Hove is reported as beneficially owning 1,518,113 shares (6.7%), reflecting shared voting and dispositive power across the named Acorn entities and calculated on 22,662,943 shares outstanding as of May 7, 2026.

What outstanding share count does the filing use to compute percentages for KPTI?

The filing uses 22,662,943 shares of Common Stock outstanding as of May 7, 2026, as reported in the issuer's Form 10‑Q for the quarter ended March 31, 2026, cited in Item 4(b).

When was the Schedule 13G signed for these KPTI disclosures?

The signatures in the excerpt show 05/15/2026 for Anders Hove in his capacities as Manager and individually. The filing cover rows list the ownership and power figures incorporated into Item 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 02:58 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Karyopharm Therapeutics Inc.

(Name of Issuer)

Common Stock, $0.0001 Par Value

(Title of Class of Securities)

48576U205

(CUSIP Number)

05/13/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 48576U205

1

Names of Reporting Persons

ACORN BIOVENTURES, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 637,608.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 637,608.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

637,608.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.8 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 48576U205

1

Names of Reporting Persons

ACORN CAPITAL ADVISORS GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 637,608.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 637,608.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

637,608.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.8 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 48576U205

1

Names of Reporting Persons

ACORN BIOVENTURES 2, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 880,505.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 880,505.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

880,505.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.9 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 48576U205

1

Names of Reporting Persons

Acorn Capital Advisors GP 2, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 880,505.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 880,505.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

880,505.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.9 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 48576U205

1

Names of Reporting Persons

Anders Hove

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,518,113.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,518,113.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,518,113.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.7 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Karyopharm Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 85 WELLS AVENUE, SECOND FLOOR, NEWTON, MASSACHUSETTS, 02459.
Item 2.
(a)	Name of person filing: Acorn Bioventures, L.P. Acorn Capital Advisors GP, LLC Acorn Bioventures 2, L.P. Acorn Capital Advisors GP2, LLC Anders Hove
(b)	Address or principal business office or, if none, residence: 420 Lexington Avenue, Suite 2626, New York, New York 10170
(c)	Citizenship: Acorn Bioventures, L.P. and Acorn Bioventures 2 L.P. are both Delaware limited partnerships. Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC are both Delaware limited liability companies. Anders Hove is a citizen of the United States of America.
(d)	Title of class of securities: Common Stock, $0.0001 Par Value
(e)	CUSIP Number(s): 48576U205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
(b)	Percent of class: The percentages set forth herein are calculated based upon 22,662,943 shares of Common Stock outstanding as of May 7, 2026 as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026 filed with the Securities and Exchange Commission on May 7, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Acorn Capital Advisors GP, LLC is the General Partner of Acorn Bioventures, L.P. and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn Bioventures, L.P. Acorn Capital Advisors GP 2, LLC is the General Partner of Acorn Bioventures 2, L.P. and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn Bioventures 2, L.P.
	(ii) Shared power to vote or to direct the vote: Anders Hove, in his capacity as Manager of each of Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC, may be deemed to beneficially own the shares beneficially owned by each of Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC.
	(iii) Sole power to dispose or to direct the disposition of: NA
	(iv) Shared power to dispose or to direct the disposition of: NA
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ACORN BIOVENTURES, L.P.

Signature:	Anders Hove
Name/Title:	Manager of General Partner
Date:	05/15/2026

ACORN CAPITAL ADVISORS GP, LLC

Signature:	Anders Hove
Name/Title:	Manager
Date:	05/15/2026

ACORN BIOVENTURES 2, L.P.

Signature:	Anders Hove
Name/Title:	Manager of General Partner
Date:	05/15/2026

Acorn Capital Advisors GP 2, LLC

Signature:	Anders Hove
Name/Title:	Manager
Date:	05/15/2026

Anders Hove

Signature:	Anders Hove
Name/Title:	Individually
Date:	05/15/2026